Apoptosis and proliferation pathway proteins

Apoptosis and proliferation pathway proteins encompass a broad and diverse group of molecules that govern the fundamental balance between cell survival and programmed cell death (NIH, 2023). These pathways include the intrinsic and extrinsic apoptotic cascades, as well as mitogenic signaling routes such as the PI3K/AKT/mTOR and MAPK/ERK pathways (PubMed, 2022). In many diseases, particularly cancer, the regulation of these proteins is disrupted, leading to uncontrolled cellular growth and resistance to cell death (StatPearls, 2024). Therapeutic intervention often involves small molecules or monoclonal antibodies designed to inhibit overactive proliferative signals or to neutralize anti-apoptotic survival proteins like BCL-2 (UniProt, 2024). Because these pathways are essential for normal tissue homeostasis, targeting them requires careful management of systemic toxicities, such as cytopenias or organ-specific adverse effects (PubChem, 2024).

Other names

Cell death and growth regulatory proteinsApoptotic and mitogenic signaling proteinsProgrammed cell death and proliferation regulators

Drugs targeting these pathways typically act by inhibiting anti-apoptotic proteins (e.g., BCL-2 inhibitors), blocking mitogenic signaling kinases (e.g., MEK or PI3K inhibitors), or restoring pro-apoptotic signaling to induce programmed cell death in malignant cells.